FAILED TRIAL: Ph 2 DeFianCe study of sirexatamab (DKN-01) in 2L CRC did not meet primary endpoint of PFS improvement August 20, 2026
ACR-2316 advances into dose expansion portion of Ph 1/2 study in SCLC, squamous NSCLC, lung adenocarcinoma (adNSCLC), endometrial, cervical, and GEJ cancers August 11, 2026
First Patient Dosed in Registrational Study of IBI363/TAK-928 in Combination with Bevacizumab in Late-Line Advanced CRC in China August 11, 2026
CRL issued for ongoing ITM-11 NDA citing CMC and third-party commercial facility inspection-related items August 11, 2026
Olomorasib receives FDA Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer August 5, 2026
IDE892 Initiates Part 2 Monotherapy Expansion in Ph 1/2 Study in MTAP-Deleted Pancreatic & Lung Cancers August 5, 2026
Final subject received last dose of Ampligen (rintatolimod) in Ph 2 DURIPANC trial of Ampligen + Imfinzi for the treatment of metastatic pancreatic cancer August 5, 2026
IND Application for Ph 1b/2 Opamtistomig Combo in Metastatic Colorectal Cancer Approved August 5, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
Sonesitatug vedotin demonstrated statistically significant OS improvement in 2L+ CLDN18.2-positive advanced gastric/GEJ cancers July 28, 2026
FDA accepts NDA for Daraxonrasib for Review for Previously Treated Metastatic Pancreatic Cancer July 28, 2026
CTA and supply agreement between Phanes & Merck to evaluate spevatamig, KEYTRUDA & chemo combo for treatment of biliary tract cancer expanded July 28, 2026
Enrollment completed in Ph 2 trial of spevatamig + chemo for the 1L metastatic pancreatic ductal adenocarcinoma July 28, 2026
Jemperli achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer July 15, 2026
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer July 15, 2026
Primary Results Announced from Ph 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs July 15, 2026
